Expert Perspectives


Sipuleucel-T Survival Benefit Greater in Black Men

Andrew J. Armstrong, MD, and colleagues looked at men with metastatic castration-resistant prostate cancer treated with sipuleucel-T in the PROCEED registry. Study findings demonstrated that African-American men experienced a substantially greater survival benefit from the immunotherapy than Caucasian men.

Subclassification of High-Risk Prostate Cancer Validated

Vinayak Muralidhar, MD, and colleagues compared a subgroup of men with favorable high-risk PCa (T1c with either a Gleason score of 4+4 = 8 and a PSA level below 10 ng/mL or a Gleason score of 6 and a PSA level greater than 20 ng/mL) with standard high-risk disease.
Mara R. Holton, MD

Meeting Highlights From LUGPA 2019

Renal & Urology News discussed the annual LUGPA meeting with Mara R. Holton, MD, who sits on LUGPA’s board of directors and is the organization’s vice chair of health policy.
Brian Helfand MD PhD

Germline Testing for Prostate Cancer Active Surveillance

Brian T. Helfand, MD, PhD, discussed germline testing for prostate cancer prognosis and its implications for active surveillance at the Philadelphia Prostate Cancer Consensus Conference: Implementation of Genetic Testing for Inherited Prostate Cancer.

Pharmacologic Therapy for CRPC

At the 2019 annual meeting of the American Urological Association (AUA), Dr Jarrard was a member of the instructional faculty in a session titled “AUA Castration Resistant Prostate Cancer (CRPC) Guidelines and Therapeutic Advances in Metastatic Prostate Cancer.”
Next post in Expert Perspectives